Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.2 USD
73.86 M USD
661.82 M USD
52.87 M
About Supernus Pharmaceuticals, Inc.
Sector
Industry
CEO
Jack A. Khattar
Website
Headquarters
Rockville
Founded
2005
ISIN
US8684591089
FIGI
BBG00JVRK635
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 0LB2 is 47.8 USD — it has increased by 0.26% in the past 24 hours. Watch Supernus Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange Supernus Pharmaceuticals, Inc. stocks are traded under the ticker 0LB2.
0LB2 stock has risen by 1.95% compared to the previous week, the month change is a 5.02% rise, over the last year Supernus Pharmaceuticals, Inc. has showed a 52.42% increase.
We've gathered analysts' opinions on Supernus Pharmaceuticals, Inc. future price: according to them, 0LB2 price has a max estimate of 63.00 USD and a min estimate of 40.00 USD. Watch 0LB2 chart and read a more detailed Supernus Pharmaceuticals, Inc. stock forecast: see what analysts think of Supernus Pharmaceuticals, Inc. and suggest that you do with its stocks.
0LB2 reached its all-time high on Jun 29, 2018 with the price of 60.8 USD, and its all-time low was 21.8 USD and was reached on Dec 14, 2020. View more price dynamics on 0LB2 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
0LB2 stock is 0.41% volatile and has beta coefficient of 0.56. Track Supernus Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Supernus Pharmaceuticals, Inc. there?
Today Supernus Pharmaceuticals, Inc. has the market capitalization of 2.69 B, it has increased by 1.46% over the last week.
Yes, you can track Supernus Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Supernus Pharmaceuticals, Inc. is going to release the next earnings report on Nov 11, 2025. Keep track of upcoming events with our Earnings Calendar.
0LB2 earnings for the last quarter are 0.91 USD per share, whereas the estimation was 0.47 USD resulting in a 93.29% surprise. The estimated earnings for the next quarter are 0.14 USD per share. See more details about Supernus Pharmaceuticals, Inc. earnings.
Supernus Pharmaceuticals, Inc. revenue for the last quarter amounts to 165.45 M USD, despite the estimated figure of 154.06 M USD. In the next quarter, revenue is expected to reach 175.82 M USD.
0LB2 net income for the last quarter is 22.50 M USD, while the quarter before that showed −11.83 M USD of net income which accounts for 290.23% change. Track more Supernus Pharmaceuticals, Inc. financial stats to get the full picture.
No, 0LB2 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 3, 2025, the company has 674 employees. See our rating of the largest employees — is Supernus Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Supernus Pharmaceuticals, Inc. EBITDA is 148.57 M USD, and current EBITDA margin is 21.42%. See more stats in Supernus Pharmaceuticals, Inc. financial statements.
Like other stocks, 0LB2 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Supernus Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Supernus Pharmaceuticals, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Supernus Pharmaceuticals, Inc. stock shows the buy signal. See more of Supernus Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.